After twenty years in the pharma sector, Michelle Werner re-entered biotech on a mission to bring Alltrna’s technology to market
Exploring Alltrna’s Rare Disease Platform
Michelle Werner, CEO of Alltrna, sat down with In Vivo to discuss rare disease as an increasingly important area of study, innovation in the space and how the emerging biotech hopes to impact the treatment landscape.
